يعرض 1 - 10 نتائج من 29 نتيجة بحث عن '"ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias del sistema digestivo::neoplasias pancreáticas"', وقت الاستعلام: 0.76s تنقيح النتائج
  1. 1
    دورية أكاديمية

    المساهمون: Institut Català de la Salut, Gardner FP Florida Cancer Specialists and Research Institute, Cape Coral, USA. Wainberg ZA UCLA School of Medicine, Los Angeles, USA. Fountzilas C Roswell Park Comprehensive Cancer Center, Buffalo, USA. Bahary N Allegheny Health Network Cancer Institute, Pittsburgh, USA. Womack MS Tennessee Oncology, Chattanooga, USA. Macarulla T Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

    العلاقة: Cancers;16(7); https://doi.org/10.3390/cancers16071323Test; Gardner FP, Wainberg ZA, Fountzilas C, Bahary N, Womack MS, Macarulla T, et al. Results of a Randomized, Double-Blind, Placebo-Controlled, Phase 1b/2 Trial of Nabpaclitaxel + Gemcitabine ± Olaratumab in Treatment-Naïve Participants with Metastatic Pancreatic Cancer. Cancers (Basel). 2024 Mar 28;16(7):1323.; https://hdl.handle.net/11351/11345Test

  2. 2
    دورية أكاديمية

    المساهمون: Institut Català de la Salut, Augustinus S Department of Surgery, Location University of Amsterdam, Amsterdam University Medical Center, Amsterdam, The Netherlands. Cancer Center Amsterdam, Amsterdam, The Netherlands. van Laarhoven HWM Cancer Center Amsterdam, Amsterdam, The Netherlands. Department of Medical Oncology, Location University of Amsterdam, Amsterdam University Medical Center, Amsterdam, The Netherlands. Cirkel GA Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands. de Groot JWB Department of Medical Oncology, Isala Oncology Center, Zwolle, The Netherlands. Groot Koerkamp B Department of Surgery, Erasmus MC Cancer Institute, Rotterdam, The Netherlands. Macarulla T Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

    العلاقة: Cancers;15(23); https://doi.org/10.3390/cancers15235603Test; Augustinus S, Van Laarhoven HWM, Cirkel GA, Willem J, De Groot B, Koerkamp BG, et al. Timing of Initiation of Palliative Chemotherapy in Asymptomatic Patients with Metastatic Pancreatic Cancer: An International Expert Survey and Case-Vignette Study. Cancers. 2023 Nov 27;15(23):5603.; https://hdl.handle.net/11351/10953Test; 001116116700001

  3. 3
    دورية أكاديمية

    المساهمون: Institut Català de la Salut, Taieb J Department of Gastroenterology and Digestive Oncology, Université de Paris, Georges Pompidou European Hospital, SIRIC CARPEM, Paris, France. Université Paris-Cité, Hôpital Européen Georges Pompidou, Hepatogastroenterology and GI Oncology, Paris, France. Seufferlein T Department of Internal Medicine I, University Hospital Ulm, Ulm, Germany. Reni M University Vita E Salute, IRCCS, San Rafaele Scientifc Institute, Milan, Italy. Palmer DH University of Liverpool, Liverpool, UK. Bridgewater JA UCL Cancer Institute, London, UK. Cubillo A HM CIOCC University Hospital, Madrid, Spain. Macarulla T Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. IOB Quiron, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

    العلاقة: BMC Cancer;23; https://doi.org/10.1186/s12885-023-11377-1Test; Taieb J, Seufferlein T, Reni M, Palmer DH, Bridgewater JA, Cubillo A, et al. Treatment sequences and prognostic/predictive factors in metastatic pancreatic ductal adenocarcinoma: univariate and multivariate analyses of a real-world study in Europe. BMC Cancer. 2023 Sep 18;23:877.; https://hdl.handle.net/11351/10358Test

  4. 4
    دورية أكاديمية

    المساهمون: Institut Català de la Salut, de Vries EGE Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. Rüschoff J Targos Molecular Pathology GmbH, Kassel, Germany. Lolkema M Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands. Tabernero J Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. UVicUCC, IOB-Quiron, Barcelona, Spain. Gianni L Michelangelo Foundation, Milan, Italy. Voest E Netherlands Cancer Institute, Amsterdam, The Netherlands. Oncode Institute, Amsterdam, The Netherlands, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

    العلاقة: Cancer Medicine;12(11); https://doi.org/10.1002/cam4.5893Test; de Vries EGE, Rüschoff J, Lolkema M, Tabernero J, Gianni L, Voest E, et al. Phase II study (KAMELEON) of single-agent T-DM1 in patients with HER2-positive advanced urothelial bladder cancer or pancreatic cancer/cholangiocarcinoma. Cancer Med. 2023 Jun;12(11):12071–83.; https://hdl.handle.net/11351/9964Test; 000980485800001

  5. 5
    دورية أكاديمية

    المساهمون: Institut Català de la Salut, Chen JW, Lof S Amsterdam UMC, Department of Surgery, Location University of Amsterdam, Amsterdam, The Netherlands. Cancer Center Amsterdam, Amsterdam, The Netherlands. van Ramshorst TME Amsterdam UMC, Department of Surgery, Location University of Amsterdam, Amsterdam, The Netherlands. Cancer Center Amsterdam, Amsterdam, The Netherlands. Department of General Surgery, Istituto Ospedaliero Fondazione Poliambulanza, Brescia, Italy. Al-Sarireh B Department of Surgery, Morriston Hospital, Swansea, UK. Bjornsson B Department of Surgery and Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden. Boggi U Department of Surgery, University Hospital of Pisa, Pisa, Italy. Pando E Servei de Cirurgia Hepatobiliopancreàtica i Trasplantaments, Vall d’Hebron Hospital Universitari, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

    العلاقة: Annals of Surgical Oncology;30; https://doi.org/10.1245/s10434-022-13054-2Test; Chen JW, van Ramshorst TME, Lof S, Al-Sarireh B, Bjornsson B, Boggi U, et al. Robot-Assisted Versus Laparoscopic Distal Pancreatectomy in Patients with Resectable Pancreatic Cancer: An International, Retrospective, Cohort Study. Ann Surg Oncol. 2023 May;30:3023–32.; https://hdl.handle.net/11351/9862Test; 000936156100002

  6. 6
    دورية أكاديمية

    المساهمون: Institut Català de la Salut, Bekaii-Saab T Division of Hematology and Medical Oncology, Mayo Clinic Arizona, Scottsdale, AZ, USA. Okusaka T Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, Japan. Goldstein D Department of Medical Oncology, Prince of Wales Hospital, Randwick, NSW, Australia. Oh DY Department of Internal Medicine, Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Integrated Major in Innovative Medical Science, Seoul National University Graduate School, Seoul, Republic of Korea. Ueno M Department of Gastroenterology, Hepatobiliary and Pancreatic Medical Oncology Division, Kanagawa Cancer Center, Kanagawa, Japan. Ioka T Oncology Center, Yamaguchi University Hospital, Yamaguchi, Japan. Tabernero J Servei d’Oncologia Mèdica, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. IOB-Quiron, UVic-UCC, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

    العلاقة: eClinicalMedicine;58; https://doi.org/10.1016/j.eclinm.2023.101897Test; Bekaii-Saab T, Okusaka T, Goldstein D, Oh DY, Ueno M, Ioka T, et al. Napabucasin plus nab-paclitaxel with gemcitabine versus nab-paclitaxel with gemcitabine in previously untreated metastatic pancreatic adenocarcinoma: an adaptive multicentre, randomised, open-label, phase 3, superiority trial. eClinicalMedicine. 2023 Apr;58:101897.; https://hdl.handle.net/11351/9288Test

  7. 7
    دورية أكاديمية

    المساهمون: Institut Català de la Salut, Søreide K Department of Gastrointestinal Surgery, HPB Unit, Stavanger University Hospital, Stavanger, Norway. Department of Clinical Medicine, University of Bergen, Bergen, Norway. Rangelova E Section of Upper GI Surgery at Department of Surgery, Sahlgrenska University Hospital, Gothenburg, Sweden. Dopazo C Servei de Cirurgia Hepatobiliopancreàtica i Trasplantaments, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Mieog S Department of Surgery, Leiden University Medical Center, Leiden, the Netherlands. Stättner S Department of General, Visceral and Vascular Surgery, Salzkammergut Klinikum, OÖG, Vöcklabruck, Austria, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

    العلاقة: European Journal of Surgical Oncology;49(2); https://doi.org/10.1016/j.ejso.2023.01.001Test; Søreide K, Rangelova E, Dopazo C, Mieog S, Stättner S. Pancreatic cancer. Eur J Surg Oncol. 2023 Feb;49(2):521–5.; https://hdl.handle.net/11351/9214Test

  8. 8
    دورية أكاديمية

    المساهمون: Institut Català de la Salut, Huebner A Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK. Cancer Genome Evolution Research Group, Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK. Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK. Black JRM Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK. Cancer Genome Evolution Research Group, Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK. Sarno F Peaches Biotech, Madrid, Spain. Pazo R Hospital Universitario Miguel Servet, Zaragoza, Spain. Juez I Hospital Universitario de Fuenlabrada, Madrid, Spain. Medina L IBIMA, Virgen de La Victoria, Malaga, Spain. Arenillas C, Toledo RA Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain. Moreno-Cárdenas AB Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Verdaguer H, Macarulla T Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf; application/vnd.openxmlformats-officedocument.spreadsheetml.sheet

    العلاقة: Genome Medicine;15; https://doi.org/10.1186/s13073-023-01171-wTest; Huebner A, Black JRM, Sarno F, Pazo R, Juez I, Medina L, et al. ACT-Discover: identifying karyotype heterogeneity in pancreatic cancer evolution using ctDNA. Genome Med. 2023 Apr 20;15:27.; https://hdl.handle.net/11351/9465Test

  9. 9
    دورية أكاديمية

    المساهمون: Institut Català de la Salut, Vera R Navarra University Hospital, Spanish Society of Medical Oncology (SEOM), Pamplona, Spain. Ibarrola-de-Andrés C, Rodríguez-Gil Y 12 de Octubre University Hospital, Spanish Society of Pathology (SEAP), Madrid, Spain. Adeva J 12 de Octubre University Hospital, Spanish Society of Medical Oncology (SEOM), Madrid, Spain. Pérez-Rojas J La Fe University and Polytechnic Hospital, Spanish Society of Pathology (SEAP), Valencia, Spain. García-Alfonso P Gregorio Marañón University Hospital, Spanish Society of Medical Oncology (SEOM), Madrid, Spain. Macarulla T Vall d’Hebron Hospital Universitari, Barcelona, Spain. Spanish Society of Medical Oncology (SEOM), Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

    العلاقة: Clinical and Translational Oncology;24; https://doi.org/10.1007/s12094-022-02873-0Test; Vera R, Ibarrola-de-Andrés C, Adeva J, Pérez-Rojas J, García-Alfonso P, Rodríguez-Gil Y, et al. Expert consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology on the determination of biomarkers in pancreatic and biliary tract cancer. Clin Transl Oncol. 2022 Nov;24:2107–19.; https://hdl.handle.net/11351/8778Test; 000844495200002

  10. 10
    دورية أكاديمية

    المساهمون: Institut Català de la Salut, Ramage JK, Friend E, King B Hampshire Hospitals NHS Foundation Trust, Basingstoke, UK. Randell J University of Winchester, Winchester, UK. Fernandez Ortega P Institut Catala d’Oncologia, Barcelona, Spain. McNamara MG Division of Cancer Sciences, University of Manchester/The Christie NHS Foundation Trust, Manchester, UK. Capdevila J Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall Hebron Institute of Oncology (VHIO), Barcelona, Spain, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

    العلاقة: Journal of Neuroendocrinology;34(4); https://doi.org/10.1111/jne.13097Test; Ramage JK, Friend E, Randell J, King B, Fernandez Ortega P, McNamara MG, et al. Development of a quality of life questionnaire for patients with pancreatic neuroendocrine tumours (the PANNET module). J Neuroendocrinol. 2022 Apr;34(4):e13097.; https://hdl.handle.net/11351/7842Test; 000754479400001